An Awesome Day: Vigilant Biosciences’ New $30 Oral Cancer Screening System Gets $5-Million Backing

March 11, 2015

Yesterday, Vigilant Biosciences introduced the world to its OncAlert Oral Cancer Risk Assessment System, the company’s revolutionary oral cancer screening and identification product. To top things off, it also announced $5 million in guaranteed purchases in a five-year exclusive distribution agreement in Korea with BL&H.

How does the system work, and what will the industry impact be? To get the answer, we interviewed Dr. John Comisi, Chief Dental Officer for Vigilant. Watch now

Source: APEX360

© 2020 Vigilant Biosciences

Follow Us

3900001 Rev1